MacTel: Navigating A New Treatment Era
Posted on February 22, 2026 by Miriah Teeter, M.D. in Past CE/CME Presentations
Presented by Miriah Teeter, M.D., Retina Specialist at Colorado Retina Associates
CRA's 2026 Mile High Masters of Retina meeting
This pre-recorded talk, provides primary eye care providers with an overview of Macular Telangiectasia and its complex pathophysiology, highlighting the first FDA-approved treatment option, ENCELTO, and its role in contemporary disease management.
CLINICAL PEARLS:
- MacTel is a genetic neuroglial degenerative disease resulting in progressive bilateral maculopathy in middle aged adults
- Encelto is the first proven MacTel treatment to help preserve macular function over time
- Early detection and referral is key to providing maximal treatment benefit
- Ongoing research into MacTel holds promise for future treatment options
